AbbVie Inc. Goodwill, Acquired During Period
AbbVie Inc. (ABBV) reported Goodwill, Acquired During Period of $170.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2026-02-20
- AbbVie Inc. goodwill, acquired during period for the quarter ending 2025-12-31 was $0.00.
- AbbVie Inc. goodwill, acquired during period for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AbbVie Inc. goodwill, acquired during period for the quarter ending 2025-06-30 was $0.00.
- AbbVie Inc. goodwill, acquired during period for the quarter ending 2025-03-31 was $170.00M, a 86.39% decline year-over-year.
- AbbVie Inc. goodwill, acquired during period for fiscal 2025 was $170.00M, a 94.24% decline from fiscal 2024.
- AbbVie Inc. goodwill, acquired during period for fiscal 2024 was $2.95B.
- AbbVie Inc. goodwill, acquired during period for fiscal 2022 was $92.00M, a 48.02% decline from fiscal 2021.
- AbbVie Inc. goodwill, acquired during period for fiscal 2021 was $177.00M, a 98.96% decline from fiscal 2020.
| Period end | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-02-20 | $170.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $170.00M 10-Q · filed 2025-11-04 | $170.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $170.00M 10-Q · filed 2025-08-04 | $170.00M derived: sum of 3 quarters · filed 2026-02-20 | $1.87B derived: sum of 4 quarters · filed 2026-02-20 |
| 2025-03-31 | $170.00M 10-Q · filed 2025-05-09 | $170.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.87B derived: sum of 3 quarters · filed 2026-02-20 | $1.87B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.70B derived: sum of 2 quarters · filed 2026-02-20 | $1.70B derived: sum of 3 quarters · filed 2026-02-20 | $2.95B 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.70B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.70B derived: sum of 2 quarters · filed 2024-11-04 | $2.95B 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.25B 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $1.25B 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $92.00M 10-K · filed 2024-02-20 | |||
| 2021-12-31 | $177.00M 10-K · filed 2023-02-17 | |||
| 2020-12-31 | -$10.05B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$10.04B derived: sum of 2 quarters · filed 2022-02-18 | $17.01B 10-K · filed 2022-02-18 | |
| 2020-09-30 | $19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $27.06B 10-Q · filed 2020-11-04 | ||
| 2020-06-30 | $27.04B 10-Q · filed 2020-08-04 | |||
| 2016-12-31 | -$42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $84.00M derived: sum of 2 quarters · filed 2018-02-16 | $2.36B 10-K · filed 2018-02-16 | |
| 2016-09-30 | $126.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $2.40B 10-Q · filed 2016-11-07 | ||
| 2016-06-30 | $2.28B 10-Q · filed 2016-08-05 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $8.00M derived: sum of 2 quarters · filed 2017-02-17 | $7.61B 10-K · filed 2017-02-17 | |
| 2015-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $7.61B 10-Q · filed 2015-11-06 | ||
| 2015-06-30 | $7.60B 10-Q · filed 2015-08-07 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $0.00 derived: sum of 2 quarters · filed 2014-02-21 | $25.00M 10-K · filed 2014-02-21 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $25.00M 10-Q · filed 2013-11-12 | ||
| 2013-06-30 | $25.00M 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |